No attention-boosting drugs for healthy kids, doctors urge

Doctors at Yale School of Medicine and the American Academy of Neurology (AAN) have called upon their fellow physicians to limit or end the practice of prescribing memory-enhancing drugs to healthy children whose brains are still developing. Their position statement is published in the March online issue of the journal Neurology, the medical journal of the AAN.

The statement was written to address the growing trend in which teens use "study drugs" before tests and parents request attention deficit hyperactivity disorder (ADHD) drugs for children who don't meet the criteria for the disorder. The AAN spent several years analyzing all of the available research and ethical issues to develop this official position statement on the topic.

"Doctors caring for children and teens have a professional obligation to always protect the best interests of the child, to protect vulnerable populations, and to prevent the misuse of medication," said first author of the statement, William Graf, M.D., professor of pediatrics and neurology at Yale School of Medicine. "The practice of prescribing these drugs, called neuroenhancements, for healthy students is not justifiable."

Graf and a group of child neurologists provide evidence that points to dozens of ethical, legal, social, and developmental reasons why prescribing mind-enhancing drugs, such as those used to treat ADHD, for healthy people is viewed differently in children and adolescents than it would be in functional, independent adults with full decision-making capacities.

Some of the reasons not to prescribe neuroenhancements include: the child's best interest; the long-term health and safety of neuroenhancements, which has not been studied in children; kids and teens may lack complete decision-making capacities while their judgments and cognitive abilities are still developing; maintaining doctor-patient trust; and the risks of over-medication and dependency.

"A physician should talk to the child about the request, as it may reflect other medical, social, or psychological motivations such as anxiety, depression, or insomnia," said Graf, who notes that there are alternatives to neuroenhancements available, including maintaining good sleep, nutrition, study habits, and exercise regimens.

Other authors on the position statement include Saskia K. Nagel, Leon G. Epstein, M.D., Geoffrey Miller, M.D., Ruth Nass, M.D., and Dan Larriviere, M.D.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]